TABLE 3.
Treatment emergent adverse events.
| Adverse events | Any grade, n (%) | Grade 3/4, n (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| T‐L‐P (n = 54) | T‐L (n = 45) | T (n = 40) | p‐value | T‐L‐P (n = 54) | T‐L (n = 45) | T (n = 40) | p‐value | |
| Elevated TB | 8 (14.8) | 10 (22.2) | 7 (17.5) | 0.844 | 1 (1.9) | 0 (0) | 0 (0) | 1.000 |
| Elevated AST | 20 (37.0) | 13 (28.9) | 11 (27.5) | 0.548 | 2 (3.7) | 1 (2.2) | 0 (0) | 0.222 |
| Elevated ALT | 25 (46.3) | 15 (33.3) | 10 (25.0) | 0.094 | 5 (9.3) | 3 (6.7) | 0 (0) | 0.137 |
| Decreased PLT | 15 (27.8) | 11 (24.4) | 4 (10.0) | 0.100 | 3 (5.6) | 1 (2.2) | 1 (2.5) | 0.734 |
| WBC decrease | 7 (13.0) | 5 (11.1) | 4 (10.0) | 0.945 | 0 (0) | 0 (0) | 0 (0) | – |
| Neutropenia | 5 (9.3) | 2 (4.4) | 1 (2.5) | 0.387 | 0 (0) | 0 (0) | 0 (0) | – |
| Decreased albumin | 2 (3.7) | 2 (4.4) | 0 (0) | 0.556 | 0 (0) | 0 (0) | 0 (0) | – |
| Hemoglobin decreased | 3 (5.6) | 1 (2.2) | 0 (0) | 0.461 | 0 (0) | 0 (0) | 0 (0) | – |
| Hypothyroidism | 2 (3.7) | 0 (0) | 0 (0) | 0.334 | 0 (0) | 0 (0) | 0 (0) | – |
| Hypertension | 16 (29.6) | 10 (22.2) | 0 (0) | <0.001 | 6 (11.1) | 4 (8.9) | 0 (0) | 0.068 |
| Hand‐foot skin reaction | 6 (11.1) | 4 (8.9) | 0 (0) | 0.068 | 2 (3.7) | 1 (2.2) | 0 (0) | 0.778 |
| Decreased appetite | 8 (14.8) | 4 (8.9) | 0 (0) | 0.027 | 0 (0) | 0 (0) | 0 (0) | – |
| Fever | 10 (18.5) | 6 (13.3) | 7 (17.5) | 0.773 | 0 (0) | 0 (0) | 0 (0) | – |
| Fatigue | 11 (20.4) | 7 (15.6) | 5 (12.5) | 0.583 | 0 (0) | 0 (0) | 0 (0) | – |
| Abdominal pain | 6 (11.1) | 7 (15.6) | 9 (22.5) | 0.326 | 0 (0) | 0 (0) | 0 (0) | – |
| Vomiting | 9 (16.7) | 4 (8.9) | 4 (10.0) | 0.519 | 0 (0) | 0 (0) | 0 (0) | – |
| Diarrhea | 6 (11.1) | 5 (11.1) | 3 (7.5) | 0.880 | 0 (0) | 0 (0) | 0 (0) | – |
| Dysphonia | 3 (5.6) | 2 (4.4) | 0 (0) | 0.443 | 0 (0) | 0 (0) | 0 (0) | – |
| proteinuria | 2 (3.7) | 2 (4.4) | 0 (0) | 0.556 | 0 (0) | 0 (0) | 0 (0) | – |
Abbreviations: AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate transaminase; PLT, platelet; T, transarterial chemoembolization; TB, total bilirubin; T‐L, transcatheter arterial chemoembolization plus lenvatinib; T‐L‐P, transcatheter arterial chemoembolization combined with lenvatinib plus programmed cell death protein‐1 inhibitors; WBC, white blood cell.